Craig Andrews has more than 34 years of experience representing public and private companies, venture capitalists and entrepreneurs.

He has extensive experience in public and private securities offerings and mergers and acquisitions, and is regularly sought out by boards of directors for corporate governance advice.

He has served as a member of the Board of Directors of many companies and organizations, including DTS, Inc. (Digital Theatre Systems, NASDAQ), Renova Therapeutics, Inc. (gene therapy for heart failure), Adipogen International, Inc., Algebraix Data Corporation, Elgar Electronics (NASDAQ, sold to Dobson Park Industries), Endonetics (sold to Medtronic), GeneFormatics (sold to Genpathway), Axxora Life Sciences (sold to Enzo Biosciences), Encad (NASDAQ, sold to Kodak), Alexis Biochemicals (sold to Qbiogene), Rubios Restaurants, Inc. (NASDAQ, sold to Mill Road Capital), Collateral Therapeutics, Inc. (NASDAQ, sold to Schering AG), The Legacy Bank (merged into Landmark Bank), the San Diego Venture Group, the UCLA Alumni Association and the San Diego County Water Authority.